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Radiographic Progression in Rheumatoid Arthritis: 
Results of 3 Comparative Trials
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ABSTRACT.
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progression were evaluated. Despite the wide range in disease duration of patients in the different 
studies, a statistically significant slowing of radiographic progression was found in those patients 
treated with aurothioglucose, sulfasalazine, and methotrexate compared to auranofin, hydroxych­
loroquine, and azathioprine, respectively. These drugs might therefore be considered as disease con­
trolling antirheumatic drugs. (J Rheumatol /995/22:1797-9)
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Rheumatoid arthritis (RA) is a chronic and inflammatory joint 
disease that often leads to destructive lesions o f  articular tis­
sues, namely cartilage and periarticular bone, that is largely 
irreversible. The aim of the treatment of RA is therefore not 
only suppression of joint inflammation and relief of concomi­
tant pain and stiffness, but also prevention or retardation of 
joint damage. In the new classification criteria, drugs that 
suppress synovial inflammation, sustain functional status and 
prevent or slow radiological destruction are called disease 
controlling antirheumatic therapies (DCART)1. At this mo­
ment it is still unclear how many of the currently available 
disease modifying antirheumatic drugs (DMARD) fulfil in 
particular this last criterion2. We present the effects of 6 
different DM ARD on radiological progression in RA. The 
results were obtained in 3 clinical trials performed in the last
15 years in our department3-5.
DMARD trials. In the 1st trial, the effects o f  gold thioglu- 
cose (GTG) injections were compared with auranofin (AF) 
treatment in patients with an established RA3. During the 
1st year o f  the study, 50% of the patients dropped out. The 
main reason for discontinuing treatment with GTG was ad­
verse reactions and in the AF group, lack of efficacy. Evalu­
ated on an intention to treat basis, the GTG treatment was 
superior to AF. Radiographs of hands and feet were taken 
at the start, after 24 and 48 weeks. The radiographs were 
read by a blinded observer (A. Larsen) following the Larsen 
method6. Evaluation was performed by both the total radio- 
graphic score as well as the number of newly developed ero­
sions after 24 and 48 weeks. A statistically significant in­
crease in the total radiographic score at 24 and 48 weeks from
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baseline was observed in the AF group and not in the GTG 
group. In the AF group but not in the GTG treated patients, 
a statistically significant increase in the mean number of new 
erosions was seen after 24 and 48 weeks (Figure 1). Although 
this study was hampered by high dropout rates, the differ­
ence between these 2 treatments might even be greater par­
ticularly as those patients in the AF group with a lack of effi­
cacy dropped out, while in the GTG group, the dropouts due 
to adverse reactions could be classified as responders7.
In the 2nd trial the effects of sulfasalazine were investigated 
as compared to hydroxychloroquine in patients with early 
RA4. In the sulfasalazine treated patients a significantly 
earlier suppression of disease activity was found compared 
to the hydroxychloroquine treated patients, although after
24 and 48 weeks no statistically significant difference was 
found between the 2 treatments for the individual disease 
activity variables8. When using a composite index, the dis­
ease activity score (DAS), statistically significant differences 
between the 2 treatments were found at various time points 
(Figure I f .  Radiographs of hands and feet were taken at the 
start, after 24 and 48 weeks and scored by a blinded observ­
er (DvdH), with the modified Sharp method. After 24 and 
48 weeks statistically significantly more radiographic damage 
was observed in the hydroxychloroquine group compared to 
the sulfasalazine group. After 48 weeks the trial course was 
broken and patients received DMARD chosen by their phy­
sicians. After 3 years the patients of the 2 treatments were 
evaluated again according to an intention to treat principle. 
The significant difference in joint damage found after 48 
weeks was still present at 3 year followup, but the number 
of new erosions and the increase in total score (summation 
of narrowing and number of erosions) was not significantly 
different in the period after 48 weeks10.
In the 3rd trial, carried out in patients with advanced RA, 
the effect o f  methotrexate (MTX) and azathioprine were 
compared11. The clinical evaluation revealed a statistically 














Fig. 1. Mean number of new erosions during the study in both treatment 





Fig. 2. Course of the disease activity in both treatment groups using the 
DAS. P <0.05, t test.
MTX. Radiographs of hands and feet at the start, after 24 
and 48 weeks were evaluated by a blinded observer follow­
ing the modified Sharp method5. Although the patient 
groups already had considerable joint damage at baseline, 
significantly fewer new erosions in the MTX group com­
pared to the azathioprine group were found after 24 and 48 
weeks. In addition, the change in the total score was also 
significantly less pronounced in the MTX group compared 
with the azathioprine group after 24 and 48 weeks.
CONCLUSIONS
The disease duration of the patients in the 3 different clini­
cal trials were different. In the 1st trial patients were included 
with a mean disease duration of 3.1 and 4.3 years in the AF 
and GTG group, respectively, in the 2nd trial patients with 
early RA were included (mean disease duration of 1.3 and 
1.1 years in the hydroxychloroquine and sulfasalazine group, 
respectively) and in the 3rd trial patients with a long disease 
duration (9.4 and 12.8 years for azathioprine and MTX 
group, respectively) were included. Despite these consider­
able differences in disease duration in all 3 studies, statisti­
cally significant differences in radiographic progression 
between the comparative agents could be found. For all 3 
studies these differences in radiographic progression were 
in accordance with the clinical evaluation of the drugs. All 
radiographs were scored by an observer who was not aware 
of the clinical and laboratory findings and the drugs the 
patients received. The radiographs were read in a sequen­
tial way for each patient under identical conditions. This 
method might be the reason that differences between treat­
ments were found in relatively small groups of patients.
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Part 2 of the symposium Methods of Scoring Radiographic Changes in Rheumatoid Arthritis
will appear in the October issue o f  The Journal
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